FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 51 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR How the history of medicine influenced our perception of cancer October 13, 2022 Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... January 18, 2024 Dame Deborah James: why do deeply personal stories resonate with us... May 24, 2022 FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... February 6, 2025 Load more HOT NEWS Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... Pembrolizumab Combinations Show Promise in mCRPC HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV...
